Aparallel controlled study on Oxcarbazepine and Lacosamide monotherapy for self-limited epilepsy with centro-temporal spikes
Objective To compare the clinical efficacy and tolerance of Oxcarbazepine(OXC)and Lacosamide(LCM)monotherapy for self-limited epilepsy with centro-temporal spikes(SeLECTS),as well as the effects on EEG and cognitive function.Methods Clinical data of 87 SeLECTS children who were treated with OXC or LCM monotherapy for 3 years in the Department of Neurology from January 2019 to December 2022 were collected for analysis.The 3-year seize-free rate,effective rate,12-month remission rate,changes in EEG and cognitive function and the occurrence of drug-related adverse events were compared between the two groups.Results A total of 87 SeLECTS children were included in this study,47 cases in the OXC group and 40 cases in the LCM group.In terms of efficacy and EEG,there was no significant difference between the two groups at 3 years follow-up.In terms of cognition,3-year follow-up,the full-scale total intelligence quotient,perceptual reasoning index,working memory index,verbal comprehension index and processing speed index of the two groups were significantly increased compared with that before treatment(all P＜0.05),while there was no significant difference between the two groups.In terms of tolerance,there was a statistically significant difference in drug-related adverse events between the OXC group and LCM groups(38.30％vs.17.50％,P=0.033).Conclusions The efficacy of LCM monotherapy in the treatment of SeLECTS is similar to OXC,with effective seizure control and better tolerability.LCM can be one of the first choices for monotherapy in SeLECTS children.LCM improved working memory better and improved perceptual reasoning earlier than OXC.
OxcarbazepineLacosamidemonotherapyself-limited epilepsy with centro-temporal spike
国家科技期刊平台
NSTL
万方数据
